Total Raised

$16.47M

Investors Count

13

Deal Terms

5

Funding, Valuation & Revenue

22 Fundings

20/20 BioLabs has raised $16.47M over 22 rounds.

20/20 BioLabs's latest funding round was a IPO for on February 19, 2026.

20/20 BioLabs's 2024 revenue was $1.75M. 20/20 BioLabs's most recent revenue is from 2024.

Sign up for a free demo to see revenue data from 2024 and more.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

2/19/2026

IPO

$XXM

0

FY undefined

3

12/13/2025

Convertible Note - IV

$0.19M

PicMii

$XXM

$1.75M

FY 2024

1

8/9/2025

Convertible Note - III

$0.56M

PicMii

$XXM

$X.XXB

((X.XXx))

FY XXXX

1

2/25/2025

Debt

$XXM

$XXM

$X.XXB

((X.XXx))

FY XXXX

10

2/1/2025

Angel - III

$XXM

$XXM

$X.XXB

((X.XXx))

FY XXXX

10

Date

2/19/2026

12/13/2025

8/9/2025

2/25/2025

2/1/2025

Round

IPO

Convertible Note - IV

Convertible Note - III

Debt

Angel - III

Amount

$0.19M

$0.56M

$XXM

$XXM

Investors

PicMii

PicMii

Valuation

$XXM

$XXM

$XXM

$XXM

$XXM

Revenue

0

FY undefined

$1.75M

FY 2024

$X.XXB

((X.XXx))

FY XXXX

$X.XXB

((X.XXx))

FY XXXX

$X.XXB

((X.XXx))

FY XXXX

Sources

3

1

1

10

10

Start free trial
New call-to-action

20/20 BioLabs Deal Terms

5 Deal Terms

20/20 BioLabs's deal structure is available for 5 funding rounds, including their Convertible Note - II from December 16, 2022.

Round

Convertible Note - II

Angel - II

Series C

Angel

Series A

Funding Date

$XXM

$XXM

$XXM

$XXM

$XXM

Pre-Money Valuation

$XXM

$XXM

$XXM

$XXM

Post-Money Valuation

$XXM

$XXM

$XXM

$XXM

Amount Raised

$XXM

$XXM

$XXM

$XXM

$XXM

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

$XXM

$XXM

$XXM

$XXM

$XXM

Board Voting

$XXM

$XXM

$XXM

$XXM

$XXM

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Convertible Note - II

$XXM

$XXM

$XXM

$XXM

$XXM

$XXM

Angel - II

$XXM

$XXM

$XXM

$XXM

$XXM

$XXM

Series C

$XXM

$XXM

$XXM

$XXM

$XXM

$XXM

Angel

$XXM

$XXM

$XXM

$XXM

$XXM

$XXM

Series A

$XXM

$XXM

$XXM

$XXM

20/20 BioLabs Investors

13 Investors

20/20 BioLabs has 13 investors. PicMii invested in 20/20 BioLabs's Convertible Note - IV funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

8/9/2025

12/13/2025

PicMii
2
Convertible Note - III, Convertible Note - IV (2025)

Equity Crowdfunding

Pennsylvania

2/1/2025

2/1/2025

WeFunder
1
Angel - III

Equity Crowdfunding

California

5/16/2020

12/16/2022

3
Angel, Angel - II (2021), Convertible Note - II (2022)

Equity Crowdfunding

California

00/00/0000

00/00/0000

SeedInvest

Subscribe to see more

Equity Crowdfunding

California

00/00/0000

00/00/0000

Ping An Venture Capital

Subscribe to see more

Corporate Venture

China

First funding

8/9/2025

2/1/2025

5/16/2020

00/00/0000

00/00/0000

Last Funding

12/13/2025

2/1/2025

12/16/2022

00/00/0000

00/00/0000

Investor

PicMii
WeFunder

SeedInvest

Ping An Venture Capital

Rounds

2
Convertible Note - III, Convertible Note - IV (2025)
1
Angel - III
3
Angel, Angel - II (2021), Convertible Note - II (2022)

Subscribe to see more

Subscribe to see more

Board Seats

Type

Equity Crowdfunding

Equity Crowdfunding

Equity Crowdfunding

Equity Crowdfunding

Corporate Venture

Location

Pennsylvania

California

California

California

China

New call-to-action

Compare 20/20 BioLabs to Competitors

Freenome Logo
Freenome

Freenome operates as a biotechnology company specializing in early cancer detection within the healthcare sector. The company develops blood tests that use multiomics technology and artificial intelligence to identify cancer at its earliest and most treatable stages. It was founded in 2014 and is based in Brisbane, California.

Owlstone Medical Logo
Owlstone Medical

Owlstone Medical focuses on breath analysis for disease detection within the healthcare sector. The company develops technology for discovering and validating biomarkers in breath, employing chemical analysis and sensor technology for diagnosis. Owlstone Medical's products and services are intended for academic, clinical, and pharmaceutical research partners involved in developing breath-based diagnostics. It was founded in 2004 and is based in Cambridge, United Kingdom.

O
OncoTAB

OncoTAB is a biotechnology company involved in cancer diagnostics and therapeutics. The company provides a blood test, Agkura4 Personal Score, that measures levels of a tumor-associated protein to assist in the early detection of breast cancer in women with dense breast tissue. Additionally, OncoTAB develops treatments for breast and pancreatic cancers. It is based in Charlotte, North Carolina.

L
Liquid Genomics

Liquid Genomics provides testing services for the detection of cancer gene mutations through blood-based testing within the healthcare and biotechnology sectors. The company utilizes digital PCR and allele-specific blocker PCR technologies to identify and quantify mutations in blood or tissue samples. Its services are aimed at the healthcare industry, focusing on cancer diagnostics and research. It is based in Torrance, California.

Accuragen Logo
Accuragen

AccuraGen specializes in cancer diagnostics within the biomedical sector, focusing on the development of liquid biopsy technology. The company offers diagnostic solutions that utilize DNA and RNA sequencing for personalized medicine, allowing for non-invasive cancer detection and monitoring. AccuraGen's rolling-circle amplification technology improves genetic alteration detection, which is important for early cancer screening and minimal residual disease monitoring. It is based in Menlo Park, California.

CirculoGene Diagnostics Logo
CirculoGene Diagnostics

CirculoGene Diagnostics operates within the healthcare sector, focusing on cancer detection and monitoring. The company provides genomic profiling of solid tumors at various stages, utilizing techniques like next-generation sequencing and polymerase chain reaction to analyze circulating free DNA and RNA. CirculoGene Diagnostics serves the healthcare and oncology sectors, offering products for the personalization and monitoring of cancer treatment plans. CirculoGene Diagnostics was formerly known as CirculoGene Theranostics, LLC. It was founded in 2015 and is based in Birmingham, Alabama.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.